Search Result

Results for "

allosteric inhibition

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) Akt (2) Amino acid Transporter (1) Amyloid-β (1) Apoptosis (9) Arrestin (1) Autophagy (2) Bacterial (1) Calcium Channel (2) Cannabinoid Receptor (1) Caspase (1) Cholinesterase (ChE) (1) CXCR (2) Dopamine Receptor (1) Dopamine Transporter (1) ERK (1) Free Fatty Acid Receptor (1) GABA Receptor (3) Galectin (1) Heme Oxygenase (HO) (1) HSP (1) iGluR (2) Isocitrate Dehydrogenase (IDH) (3) Keap1-Nrf2 (1) Kinesin (2) mAChR (1) mGluR (6) Monoamine Transporter (1) mTOR (1) MyD88 (1) NF-κB (1) NO Synthase (1) Opioid Receptor (1) p38 MAPK (4) PDHK (1) PERK (1) Phosphatase (1) Phosphoglycerate Dehydrogenase (PHGDH) (1) PI3K (2) Potassium Channel (1) Protease Activated Receptor (PAR) (1) Ras (2) Reference Standards (3) SHP2 (2) Sirtuin (2) Toll-like Receptor (TLR) (1) YAP (1)
By Research Areas:	Cancer (20) Cardiovascular Disease (3) Endocrinology (2) Infection (2) Inflammation/Immunology (6) Metabolic Disease (5) Neurological Disease (17)

By Targets:

5-HT Receptor (1)

Adrenergic Receptor (1)

Akt (2)

Amino acid Transporter (1)

Amyloid-β (1)

Apoptosis (9)

Arrestin (1)

Autophagy (2)

Bacterial (1)

Calcium Channel (2)

Cannabinoid Receptor (1)

Caspase (1)

Cholinesterase (ChE) (1)

CXCR (2)

Dopamine Receptor (1)

Dopamine Transporter (1)

ERK (1)

Free Fatty Acid Receptor (1)

GABA Receptor (3)

Galectin (1)

Heme Oxygenase (HO) (1)

HSP (1)

iGluR (2)

Isocitrate Dehydrogenase (IDH) (3)

Keap1-Nrf2 (1)

Kinesin (2)

mAChR (1)

mGluR (6)

Monoamine Transporter (1)

mTOR (1)

MyD88 (1)

NF-κB (1)

NO Synthase (1)

Opioid Receptor (1)

p38 MAPK (4)

PDHK (1)

PERK (1)

Phosphatase (1)

Phosphoglycerate Dehydrogenase (PHGDH) (1)

PI3K (2)

Potassium Channel (1)

Protease Activated Receptor (PAR) (1)

Ras (2)

Reference Standards (3)

SHP2 (2)

Sirtuin (2)

Toll-like Receptor (TLR) (1)

YAP (1)

By Research Areas:

Cancer (20)

Cardiovascular Disease (3)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (6)

Metabolic Disease (5)

Neurological Disease (17)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-W011102

S-Trityl-L-cysteine 2 Publications Verification NSC 83265; S-Tritylcysteine; 3-Tritylthio-L-alanine	Kinesin Apoptosis	Cancer
S-Trityl-L-cysteine (NSC 83265) is a selective and allosteric kinesin Eg5 inhibitor with an IC₅₀ of 1 μM for the inhibition of basal ATPase activity and 140 nM for the microtubule-activated ATPase activity. S-Trityl-L-cysteine has antitumor activities .

HY-13965

Parmodulin 2 5 Publications Verification ML161	Protease Activated Receptor (PAR)	Cardiovascular Disease
Parmodulin 2 (ML161) is an allosteric inhibitor of protease-activated receptor 1 (PAR1) with an IC₅₀ of 0.26 μM . Parmodulin 2 is a potent and non-competitive inhibitor of SFLLRN-induced P-selectin expression leading to inhibition of platelet aggregation in vitro and platelet thrombus formation in vivo .

HY-P0172

ATI-2341 4 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-116152

Cipepofol Ciprofol; HSK3486	GABA Receptor Sirtuin Keap1-Nrf2 Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Cipepofol (Ciprofol), a novel 2,6-disubstituted phenol derivative, is a positive allosteric modulator and direct agonist of the GABA_A receptor. Cipepofol can cause the central nerve inhibition and promote sleep based on the structural modification of Propofol (HY-B0649). Cipepofol can activate the sirtuin1 (Sirt1)/Nrf2 pathway. Cipepofol protects the heart against Isoproterenol (ISO; HY-B0468)-induced myocardial infarction by reducing cardiac oxidative stress, inflammatory response and cardiomyocyte apoptosis .

HY-125176

G907 1 Publications Verification	Bacterial	Infection
G907 is a selective antagonist of ATP-binding cassette (ABC) transporter MsbA with anti-microbial activity. G907 inhibits E. coli MsbA with an IC₅₀ value of 18 nM. G907 traps MsbA in an inward-facing, lipopolysaccharide-bound conformation by wedging into an architecturally conserved transmembrane pocket .

HY-19934

Pifusertib TAS-117	Akt Apoptosis Autophagy	Cancer
Pifusertib (TAS-117) is a potent, selective, orally active allosteric Akt inhibitor (with IC₅₀s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib induces apoptosis and autophagy .

HY-120645

BMS-986122 1 Publications Verification	Opioid Receptor	Neurological Disease
BMS-986122 is a selective, potent positive allosteric modulator of the mu-opioid receptor (µ-OR). BMS-986122 shows potentiation of orthosteric agonist-mediated β-arrestin recruitment, adenylyl cyclase inhibition, and G protein activation. BMS-986122 potentiates DAMGO-mediated [ ³⁵S]GTPγS binding in mouse brain membranes .

HY-101165

Cyclothiazide 2 Publications Verification	iGluR GABA Receptor	Neurological Disease
Cyclothiazide is a positive allosteric modulator of ionotropic AMPA-type glutamate receptors. Cyclothiazide inhibits GABA_A receptors. Cyclothiazide is frequently used to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current. Cyclothiazide can potentiate responses to kainate in hippocampal neurons. Cyclothiazide has effects on glutamatergic neurotransmission. Cyclothiazide also induces epileptiform EEG activity accompanying behavioral seizures .

HY-19934A

Pifusertib hydrochloride TAS-117 hydrochloride	Akt Apoptosis Autophagy	Cancer
Pifusertib (TAS-117) hydrochloride is a potent, selective, orally active allosteric Akt inhibitor (with IC₅₀s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib hydrochloride triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib hydrochloride induces apoptosis and autophagy .

HY-124611

JG-231	HSP Apoptosis	Cancer
JG-231 is an allosteric inhibitor of heat shock protein 70 (Hsp70). JG - 231 inhibits the binding of Hsp70 and BAG family proteins, including inhibition of Hsp70 and BAG1 with a K_i of 0.11 μM. JG-231 inhibits proliferation of tumor cells and induces apoptosis. JG-231 has antitumor activity .

HY-P0172A

ATI-2341 TFA 4 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-122255

LY487379	mGluR	Neurological Disease
LY487379 is a selective human mGluR2 positive allosteric modulator (PAM). LY487379 potentiates glutamate-stimulated [ ³⁵S]GTPγS binding with EC₅₀ values of 1.7 μM and >10 μM for mGlu2 and mGlu3 receptors respectively. LY487379 promotes cognitive flexibility and facilitates behavioral inhibition in a rat model. LY487379 can be used for schizophrenia research .

HY-112289

IDH889	Isocitrate Dehydrogenase (IDH)	Cancer
IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC₅₀s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 ^R132H, IDH1 ^R132C and IDH1 ^wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC₅₀ of 0.014 μM .

HY-103572

MNI137	mGluR	Neurological Disease
MNI137 is a potent and selective negative allosteric modulator for group II mGluRs. MNI137 has IC₅₀s values of 8.3 and 12.6 nM for human and rat mGlu2 inhibition of glutamate-induced calcium mobilization .

HY-146223

AZD4625	Ras p38 MAPK PI3K Apoptosis	Cancer
AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRAS^G12C inhibitor with an IC₅₀ of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRAS^G12C mutations. AZD4625 can be used for the study of KRAS^G12C mutant non-small cell lung cancer .

HY-179395

TEAD-IN-23	YAP	Cancer
TEAD-IN-23 (Compound 22) is an efficient pan-TEAD inhibitor with an IC₅₀ of 10 nM. TEAD-IN-23 exhibits potent anti-proliferative activity in both NCI-H226 and MSTO-211H. TEAD-IN-23 causes complete tumor regression in the MSTO-211H xenograft tumor model. TEAD-IN-23 can be used for the study of mesothelioma and hepatocellular carcinoma .

HY-176890

JTT251	PDHK	Cancer
JTT251 is a PDHK inhibitor. JTT251 binds to the allosteric lipoamidebinding domain, resulting in only partial inhibition of PDHK enzymatic activity. JTT251 can be used for the research of cancer .

HY-163532

FLS-359	Sirtuin	Infection
FLS-359 is a selective, orally active allosteric modulator for sirtuin 2, with the IC₅₀ of 3 μM. FLS-359 exhibits antiviral activity against RNA and DNA virus, through inhibition of DNA/RNA replication .

HY-121140

AZ1729	Free Fatty Acid Receptor	Metabolic Disease
AZ1729 is a potent free fatty acid 2 receptor (FFA2) activator, acting as a direct allosteric agonist and as a positive allosteric modulator. AZ1729 increases the activity of the endogenously produced short chain fatty acid propionate in G_i-mediated pathways, but not at those transduced by G_q/G₁₁. AZ1729 induces inhibition of isoproterenol-induced lipolysis in mouse adipocytes. AZ1729 also can Induce migration of human neutrophils. AZ1729 can be used for researching the signaling pathways of the physiological roles of FFA2 .

HY-175532

M4 mAChR Modulator-2	mAChR	Neurological Disease
M4 mAChR Modulator-2 is an orally active, selective, brain-penetrant positive allosteric modulator (PAM) of the M4 muscarinic acetylcholine receptor (M4 mAChR) (EC₅₀ = 513 nM). M4 mAChR Modulator-2 exhibits high target selectivity, showing negligible affinity and low inhibition rates for non-target receptors (D1R/D2R/D3R, 5-HT subtypes, κ/δ/μ opioid receptors, H1, M1/M2) while specifically binding to M4 mAChR with a K_i of 377 nM and an inhibition rate of 62.8%. M4 mAChR Modulator-2 reverses Dizocilpine (MK-801) (HY-15084B)-induced hyperlocomotion in mice. M4 mAChR Modulator-2 can be used for the study of schizophrenia

HY-146223A

(3R,10R,14aS)-AZD4625	Ras PI3K p38 MAPK Apoptosis	Cancer
(3R,10R,14aS)-AZD4625 is the isomer of AZD4625 (HY-146223), and can be used as an experimental control. AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRAS^G12C inhibitor with an IC₅₀ of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRAS^G12C mutations. AZD4625 can be used for the study of KRAS^G12C mutant non-small cell lung cancer .

HY-150056

CB1R Allosteric modulator 3	Cannabinoid Receptor Arrestin	Neurological Disease
CB1R Allosteric modulator 3 is a *CB1R positive allosteric* modulator*. CB1R Allosteric* modulator 3 has potent inhibition of cAMP and β-Arrestin with EC₅₀ values of 0.018 μM and 1.241 μM, respectively .

HY-141524

RMC-3943	SHP2 Phosphatase	Cancer
RMC-3943 is an allosteric SHP2 inhibitor (inhibition of full-length SHP2 in biochemical assay, IC₅₀ = 2.19 nM) .

HY-103562

DMeOB 3,3'-Dimethoxybenzaldazine	mGluR	Neurological Disease
DMeOB (3,3'-Dimethoxybenzaldazine) is a mGluR5 receptor negative allosteric modulator with an IC₅₀ of 3 μM. DMeOB displays reversible non-competitive inhibition of mGlu5-mediated responses .

HY-10084

CK0106023	Kinesin	Cancer
CK0106023 is a potent and specific allosteric inhibitor of KSP with a K_i value of 12 nM, showing antitumor activity. CK0106023 causes mitotic arrest and growth inhibition in several tumor cell lines. CK0106023 exhibits antitumor activity in tumor-bearing mice .

HY-121736

AGI-12026 AGI-026	Isocitrate Dehydrogenase (IDH)	Neurological Disease
AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma .

HY-P10010

DB21, Galectin-1 Antagonist	Galectin	Cancer
DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin-1 (GAL1)binding to cell surface glycans. DB21, Galectin-1 Antagonis increases inhibition of angiogenesis and tumour growth in melanoma, lung adenocarcinoma and ovarian cancer models .

HY-103552

LY487379 hydrochloride	mGluR	Neurological Disease
LY487379 hydrochloride is a selective human mGluR2 positive allosteric modulator (PAM). LY487379 hydrochloride potentiates glutamate-stimulated [ ³⁵S]GTPγS binding with EC₅₀ values of 1.7 μM and >10 μM for mGlu2 and mGlu3 receptors respectively. LY487379 hydrochloride promotes cognitive flexibility and facilitates behavioral inhibition in a rat model. LY487379 hydrochloride can be used for schizophrenia research .

HY-120355A

AP14145 hydrochloride	Potassium Channel	Cardiovascular Disease
AP14145 hydrochloride is a potent K_Ca2 (SK) channel negative allosteric modulator with an IC₅₀ of 1.1 μM for K_Ca2.2 (SK2) and K_Ca2.3 (SK3) channels. AP14145 hydrochloride inhibition strongly depends on two amino acids, S508 and A533 in the channel. AP14145 hydrochloride prolonged atrial effective refractory period (AERP) in rats and demonstrates antiarrhythmic effects in a Vernakalant-resistant porcine model of atrial fibrillation (AF) .

HY-101165R

Cyclothiazide (Standard)	Reference Standards iGluR GABA Receptor	Neurological Disease
Cyclothiazide (Standard) is the analytical standard of Cyclothiazide. This product is intended for research and analytical applications. Cyclothiazide is a positive allosteric modulator of ionotropic AMPA-type glutamate receptors. Cyclothiazide inhibits GABA_A receptors. Cyclothiazide is frequently used to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current. Cyclothiazide can potentiate responses to kainate in hippocampal neurons. Cyclothiazide has effects on glutamatergic neurotransmission. Cyclothiazide also induces epileptiform EEG activity accompanying behavioral seizures .

HY-118285

Ro4491533	mGluR	Neurological Disease
Ro4491533 is a selective, negative allosteric mGluR2/3 receptor modulator that is equally effective on both subtypes. Ro4491533 can completely block glutamate-induced calcium mobilization and glutamate-induced [35S]GTPγS binding accumulation. Ro4491533 has good pharmacokinetic properties in mice and rats, high oral bioavailability, and can pass through the blood-brain barrier. Ro4491533 can also reverse the motor inhibition effect of LY379268 in mice and show antidepressant activity in the forced swim test and tail suspension test.

HY-112289B

(1R)-IDH889	Isocitrate Dehydrogenase (IDH)	Cancer
(1R)-IDH889 is the isomer of IDH889 (HY-112289), and can be used as an experimental control. IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC₅₀s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 ^R132H, IDH1 ^R132C and IDH1 ^wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC₅₀ of 0.014 μM .

HY-183936

SDUY127	SHP2 p38 MAPK ERK	Cancer
SDUY127 is a bivalent SHP2 inhibitor with an IC₅₀ value of 16 nM. SDUY127 binds simultaneously to the tunnel allosteric site and latch allosteric site of SHP2 at a 1:1 stoichiometric ratio, stabilizes the protein in an inactive conformation, and induces sustained inhibition of the MAPK signaling pathway. SDUY127 can be used in research related to leukemia and hepatocellular carcinoma .

HY-119119

ATV399	NO Synthase Apoptosis	Metabolic Disease Inflammation/Immunology
ATV399 is an inducible nitric oxide synthase (iNOS) inhibitor. ATV399 reduces NO production via allosteric inhibition of iNOS dimerization, thereby protecting rat pancreatic islet β-cells from cytokine-induced mitochondrial stress, endoplasmic reticulum stress, and apoptosis. ATV399 can be used in research related to type 1 diabetes .

HY-103572R

MNI137 (Standard)	Reference Standards mGluR	Neurological Disease
MNI137 (Standard) is the analytical standard of MNI137 (HY-103572). This product is intended for research and analytical applications. MNI137 is a potent and selective negative allosteric modulator for group II mGluRs. MNI137 has IC₅₀s values of 8.3 and 12.6 nM for human and rat mGlu2 inhibition of glutamate-induced calcium mobilization .

HY-W069974

Ca2+ -Langerin-IN-1	Calcium Channel	Inflammation/Immunology
Ca2+-Langerin-IN-1 (Compound 3) is a allosteric Langerin inhibitor. Langerin is a C-type lectin that is expressed on Langerhans cells and plays a crucial role in pathogen recognition and innate immune activation. The K_D value of the CRD domain of murine Langerin protein for Ca2+-Langerin-IN-1 is 17 μM under the presence of Ca²⁺ and 53 μM under the absence of Ca²⁺ competition. Ca2+-Langerin-IN-1 induces conformational changes and competitively replaces Ca²⁺, thereby inhibiting the carbohydrate recognition function of the protein. Ca2+-Langerin-IN-1 can be used in the research of immunomodulatory therapy .

HY-179621

EQ-04	Cholinesterase (ChE) Amyloid-β	Neurological Disease
EQ-04 is a highly selective positive allosteric modulator (PAM) of α7 nAChR. EQ-04 has no direct inhibitory activity on AChE and BChE. EQ-04 inhibits Aβ aggregation. EQ-04 has safe cytotoxicity and potent neuroprotective activity. EQ-04 can be used for the study of Alzheimer's disease.

HY-182091

CYD-1-79	5-HT Receptor Dopamine Receptor Dopamine Transporter Adrenergic Receptor Calcium Channel	Neurological Disease
CYD-1-79 is a selective positive allosteric modulator of 5-HT2C receptor. CYD-1-79 potentiates 5-HT-evoked intracellular calcium release via a topographically distinct allosteric site. CYD-1-79 shows significant inhibition of binding at dopamine D3 receptor, DAT, and α2A/α2B adrenergic receptors. CYD-1-79 modulates 5-HT2C receptor-mediated spontaneous ambulation in rodents and synergizes with a low dose of a 5-HT2C receptor agonist. CYD-1-79 attenuates relapse vulnerability of psychoactive substance in a rodent self-administration model. CYD-1-79 can be used for the research of neurological disease .

HY-179652

PHGDH-IN-6	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-6 (Compound L5) is a PHGDH allosteric inhibitor with an IC₅₀ of 2.5 μM. PHGDH-IN-6 can be used for studying diseases related to serine synthesis .

HY-179568

F3288-0031	Monoamine Transporter	Neurological Disease
F3288-0031 is a brain-penetrant norepinephrine transporter (NET) allosteric inhibitor with inhibitory rates of 73.5% at 20 μM. F3288-0031 binds within the inner vestibule of NET, stabilizing the inward-open state and has a preferential NET/SERT inhibition with pIC₅₀ = 5.9. F3288-0031 shows no detectable off-target functional activity in vitro. F3288-0031 demonstrates robust antidepressant-like efficacy in vivo without confounding locomotor effects, F3288-0031 can be used for depressive disorder and related neuropsychiatric conditions .

HY-150108

RMC-4745	mTOR Apoptosis Caspase	Cancer
RMC-4745 is a selective dual-site inhibitor of mTORC1, with a selectivity of 35 times for mTORC1 and mTORC2. RMC-4745 inhibits the proliferation of MCF-7 cells and upregulates Caspase-3/7 activity to induce cell apoptosis. RMC-4745 does not cause the upregulation of HER3 due to the inhibition of mTORC2. RMC-4745 can be used for the study of breast cancer .

HY-179581

SLC6A19-IN-4	Amino acid Transporter	Metabolic Disease
SLC6A19-IN-4 is an allosteric-competitive and orally active B ⁰AT1 inhibitor. SLC6A19-IN-4 inhibits both human and mouse B ⁰AT1 with IC₅₀ values of 513 nM and 295 nM, respectively. SLC6A19-IN-4 exhibits excellent metabolic stability. SLC6A19-IN-4 significantly increases urinary phenylalanine (Phe) excretion and reduces plasma Phe levels through dual inhibition of B ⁰AT1 in both the intestine (reducing absorption) and kidney (promoting excretion) in vivo. SLC6A19-IN-4 can be used for phenylketonuria (PKU) and other disorders involving SLC6-family transporters research .

HY-W097625R

6-Methoxyflavone (Standard)	Toll-like Receptor (TLR) MyD88 p38 MAPK NF-κB Heme Oxygenase (HO) Reference Standards PERK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
6-Methoxyflavone (Standard) is the analytical standard of 6-Methoxyflavone (HY-W097625). This product is intended for research and analytical applications. 6-Methoxyflavone is an orally active methoxyflavone. 6-Methoxyflavone suppresses neuroinflammation in microglia through the inhibition of TLR4/MyD88/p38 MAPK/NF-κB dependent pathways and the activation of HO-1/NQO-1 signaling. 6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway and activates the PERK/EIF2a/ATF4/CHOP pathway in HeLa cells. 6-Methoxyflavone acts as a Flumazenil (HY-B0009)-insensitive positive allosteric modulator at human recombinant α1β2γ2L and α2β2γ2L GABAα receptors. 6-Methoxyflavone inhibits NFAT Translocation into the nucleus and suppresses T cell activation. 6-Methoxyflavone partially restores chronic ethanol-induced behavioral deficits in mice. 6-Methoxyflavone antagonizes chronic constriction injury and diabetes associated neuropathic nociception expression. 6-Methoxyflavone can be used for the study of cancer, inflammation and neurological diseases .

Cat. No.	상품명	Target	Research Area